2015
Evidence of Mild Liver Dysfunction Identifies Stable Heart Failure Outpatients with Reversible Renal Dysfunction
Brisco MA, Cheng SJ, Laur O, Kula AJ, Testani JM. Evidence of Mild Liver Dysfunction Identifies Stable Heart Failure Outpatients with Reversible Renal Dysfunction. Cardiorenal Medicine 2015, 5: 229-236. PMID: 26195975, PMCID: PMC4478303, DOI: 10.1159/000430505.Peer-Reviewed Original ResearchReversible renal dysfunctionStable HF outpatientsMild liver dysfunctionAlanine aminotransferaseAspartate aminotransferaseHF outpatientsRenal dysfunctionElevated bilirubinLiver dysfunctionHeart failurePoor perfusionBeta-Blocker EvaluationDecompensated heart failureHeart failure outpatientsGlomerular filtration rateSigns of congestionBaseline characteristicsRenal functionPathophysiologic factorsLiver parametersFiltration ratePatientsDysfunctionOutpatientsBilirubin
2013
Biochemical Evidence of Mild Hepatic Dysfunction Identifies Decompensated Heart Failure Patients With Reversible Renal Dysfunction
Brisco MA, McCauley BD, Chen J, Parikh CR, Testani JM. Biochemical Evidence of Mild Hepatic Dysfunction Identifies Decompensated Heart Failure Patients With Reversible Renal Dysfunction. Journal Of Cardiac Failure 2013, 19: 739-745. PMID: 24263117, PMCID: PMC3884639, DOI: 10.1016/j.cardfail.2013.10.005.Peer-Reviewed Original ResearchConceptsReversible renal dysfunctionRenal dysfunctionLiver dysfunctionElevated international normalized ratioDecompensated heart failure patientsBaseline renal dysfunctionCharacteristic laboratory abnormalitiesDecompensated HF patientsLiver dysfunction resultsSigns of HFGlomerular filtration rateHeart failure patientsMild liver dysfunctionInternational normalized ratioIntrinsic kidney diseaseBiochemical evidenceHF patientsFailure patientsLaboratory abnormalitiesRenal functionPathophysiologic factorsDischarge diagnosisKidney diseaseMultifactorial pathophysiologyNormalized ratio
2008
Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group
Ramanathan R, Egorin M, Takimoto C, Remick S, Doroshow J, LoRusso P, Mulkerin D, Grem J, Hamilton A, Murgo A, Potter D, Belani C, Hayes M, Peng B, Ivy S. Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group. Journal Of Clinical Oncology 2008, 26: 563-569. PMID: 18235115, DOI: 10.1200/jco.2007.11.0304.Peer-Reviewed Original ResearchConceptsNausea/vomitingLiver dysfunctionLiver functionLD groupNational Cancer Institute Organ Dysfunction Working GroupLiver function test elevationsPlasma concentration-time curveD dose levelDose of imatinibDoses of imatinibSevere liver dysfunctionDose-limiting toxicityMild liver dysfunctionSerum total bilirubinNormal liver functionPharmacokinetics of imatinibDose-normalized areaConcentration-time curveConcentrations of imatinibImatinib doseAdvanced malignanciesImatinib exposureMaximal doseImatinib mesylateRenal excretion
2006
Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma
Ling J, Herbst R, Mendelson D, Eckhardt S, O’Dwyer P, Ebbinghaus S, Osborne R, Cheu M, Lieberman G, Lum B. Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. Journal Of Clinical Oncology 2006, 24: 3047-3047. DOI: 10.1200/jco.2006.24.18_suppl.3047.Peer-Reviewed Original ResearchApo2L/TRAILCohort 1PK dataSerum concentrationsCohort 2Preclinical modelsRecombinant human Apo2L/TRAILPhase 1a studyPhase 1a trialMild liver dysfunctionNon-compartmental analysisTumor xenograft modelSensitive ELISA assayLiver dysfunctionLiver metastasesPK assessmentAdvanced cancerHepatic metastasesIV infusionNonclinical modelsHematologic cancersXenograft modelClinical developmentDay 1Dose levels
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply